Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Diaz Saravia

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cardio-Oncology (London, England)|June 19, 2026
A rare case of fulminant talquetamab-induced myocarditis presenting as a STEMI mimickerEric J Kim, Sara Diaz Saravia, Gagan Sahni
International Journal of Cardiology. Cardiovascular Risk and Prevention|September 22, 2025
Cancer as a novel risk factor for major cardiovascular adverse events in secondary preventionRenzo Melchiori, Sara Diaz Saravia, Pablo M Rubio, et al.
American Journal of Hematology|March 15, 2024
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, et al.
Cureus|July 24, 2024
The Interplay Between Cardiovascular Disease and Lung CancerLuka Katic, James Choi, Sara Diaz Saravia, et al.
Cardio-Oncology (London, England)|December 23, 2025
Cardiogenic shock in cancer: differences in use of temporary mechanical circulatory support, invasive hemodynamic assessment and patient outcomesSara Diaz Saravia, Vincent Torelli, Maninderjit Ghotra, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cardio-Oncology (London, England)|June 19, 2026
A rare case of fulminant talquetamab-induced myocarditis presenting as a STEMI mimickerEric J Kim, Sara Diaz Saravia, Gagan Sahni
International Journal of Cardiology. Cardiovascular Risk and Prevention|September 22, 2025
Cancer as a novel risk factor for major cardiovascular adverse events in secondary preventionRenzo Melchiori, Sara Diaz Saravia, Pablo M Rubio, et al.
American Journal of Hematology|March 15, 2024
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, et al.
Cureus|July 24, 2024
The Interplay Between Cardiovascular Disease and Lung CancerLuka Katic, James Choi, Sara Diaz Saravia, et al.
Cardio-Oncology (London, England)|December 23, 2025
Cardiogenic shock in cancer: differences in use of temporary mechanical circulatory support, invasive hemodynamic assessment and patient outcomesSara Diaz Saravia, Vincent Torelli, Maninderjit Ghotra, et al.
Pageof 1